Syndax Pharmaceuticals, Inc.
Informe acción NasdaqGS:SNDX
Capitalización de mercado: US$1.9b
Syndax Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 0/6 Los beneficios de Syndax Pharmaceuticals han disminuido a una tasa media anual de -37.2%, mientras que en la industria Biotechs los beneficios crecieron en un 19.3% anualmente. Los ingresos han ido creciendo a una tasa media de 6.2% al año.
Información clave
-37.2%
Tasa de crecimiento de los beneficios
-15.0%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs 17.0% Tasa de crecimiento de los ingresos 6.2% Rentabilidad financiera -81.1% Margen neto -1,856.6% Última actualización de beneficios 30 Sep 2024
Actualizaciones de resultados anteriores recientes
Syndax Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 29
Syndax Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 25
Syndax Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 21
Syndax Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 27
Syndax Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 26
Mostrar todas las actualizaciones
Consensus revenue estimates increase by 197% Nov 12
Syndax Pharmaceuticals, Inc. Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™? (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting Nov 05
Syndax Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 29
We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully Oct 14
Syndax Pharmaceuticals: Navigating Through A Pivotal Year Sep 20
Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) Aug 15
Consensus revenue estimates fall by 21% Aug 01
Syndax Announces Pdufa Action Date Extension for Revumenib Nda for Relapsed or Refractory Kmt2ar Acute Leukemia Jul 30
Syndax Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 25 Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Index
Consensus revenue estimates increase by 12% Jun 28
Syndax: Gearing Up For Launches Jun 21
Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth Jun 20
SSyndax Pharmaceuticals, Inc. Presents Updated Positive Data from BEAT AML and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress Jun 17
Syndax Pharmaceuticals Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC Jun 08
Syndax Pharmaceuticals, Inc. Announces Board Changes May 16
Syndax Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session Apr 09
Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024 Apr 03
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia Mar 28
Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope Mar 28
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia Mar 27
Syndax Pharmaceuticals, Inc. Announces Executive Changes Mar 19
Consensus EPS estimates fall by 23% Mar 05
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation Mar 04
Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 21 Syndax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999985 million.
Syndax Pharmaceuticals Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting Dec 13
Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease Dec 11
Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount? Nov 20
Syndax Pharmaceuticals Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting Nov 03
Syndax Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 27
Syndax Pharmaceuticals Announces to Initiate Nda Submission of Revumenib in Relapsed/Refractory Kmt2ar Acute Leukemia Under Fda's Real-Time Oncology Review Program Oct 25
Syndax Pharmaceuticals Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stated Interim Analysis Oct 05
Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth Sep 27
Director notifies of intention to sell stock Aug 13
Syndax Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 26
Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease Jul 25
Director notifies of intention to sell stock Jul 13
Consensus revenue estimates decrease by 11%, EPS upgraded Jun 27
Director exercised options and sold US$715k worth of stock Jun 11
Director exercised options and sold US$794k worth of stock May 12
Syndax Pharmaceuticals, Inc. Announces Executive Changes May 10
President exercised options and sold US$695k worth of stock Apr 13
President exercised options and sold US$853k worth of stock Mar 15
Consensus EPS estimates fall by 21% Mar 07
Co-Founder & Chief Scientific Officer notifies of intention to sell stock Feb 20
President exercised options and sold US$1.1m worth of stock Feb 09
Price target increased by 7.6% to US$34.44 Feb 01
Independent Director exercised options and sold US$616k worth of stock Jan 15 Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
Co-Founder & Chief Scientific Officer exercised options and sold US$467k worth of stock Dec 04
Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer Dec 03
Insufficient new directors Nov 16
Consensus revenue estimates increase by 64% Nov 10
Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021) Nov 04
Syndax Pharmaceuticals, Inc. Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of Augment-101 Trial of Revumenib in Patients with Acute Leukemias Nov 04
Syndax Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
CEO & Director exercised options and sold US$549k worth of stock Oct 05
President exercised options and sold US$4.4m worth of stock Sep 17
Co-Founder & Chief Scientific Officer exercised options and sold US$468k worth of stock Aug 27
Consensus forecasts updated Aug 15
Independent Director exercised options and sold US$331k worth of stock Aug 11
First half 2022 earnings released Aug 09
Syndax Pharmaceuticals Q2 2022 Earnings Preview Aug 07
Syndax Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Aug 03
Insufficient new directors Aug 02
CEO & Director exercised options and sold US$464k worth of stock Jul 28
President exercised options and sold US$735k worth of stock Jul 06
Investor sentiment improved over the past week Jun 23
Syndax Pharmaceuticals, Inc. Announces Appointment of Keith A. Goldan as Chief Financial Officer Jun 14
Investor sentiment improved over the past week May 31
Consensus forecasts updated May 16
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 10
Syndax Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 09, 2022 May 03
Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs Apr 08
President exercised options and sold US$486k worth of stock Apr 06
Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022 Mar 31
Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022 Mar 30
Consensus forecasts updated Mar 08
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 04
Syndax Pharmaceuticals, Inc. Announces Executive Changes Mar 03
Syndax Pharmaceuticals, Inc. Announces Executive Changes Feb 25
Syndax Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 24
Price target increased to US$31.67 Feb 16 Syndax Pharmaceuticals, Inc. Announces Executive Changes
Chief Medical Officer & Senior VP exercised options to buy US$131k worth of stock. Jan 04
President exercised options and sold US$462k worth of stock Dec 17
Price target increased to US$30.60 Dec 16
Syndax Pharmaceuticals, Inc. Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 Dec 15
Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease Dec 12
Independent Director notifies of intention to sell stock Nov 23
Desglose de ingresos y gastos
Cómo gana y gasta dinero Syndax Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos NasdaqGS:SNDX Ingresos, gastos y beneficios (USD Millions) Fecha Ingresos Beneficios Gastos G+A Gastos de I+D 30 Sep 24 16 -297 106 167 30 Jun 24 4 -264 92 165 31 Mar 24 0 -241 78 185 31 Dec 23 0 -209 67 163 30 Sep 23 0 -176 54 42 30 Jun 23 0 -160 45 65 31 Mar 23 0 -153 38 123 31 Dec 22 0 -149 33 118 30 Sep 22 127 -14 30 111 30 Jun 22 139 1 29 109 31 Mar 22 139 15 26 96 31 Dec 21 140 25 25 88 30 Sep 21 14 -92 23 80 30 Jun 21 2 -91 22 69 31 Mar 21 2 -86 22 63 31 Dec 20 2 -77 23 50 30 Sep 20 2 -71 23 44 30 Jun 20 2 -63 21 40 31 Mar 20 2 -61 18 41 31 Dec 19 2 -56 16 43 30 Sep 19 2 -61 15 49 30 Jun 19 2 -65 15 53 31 Mar 19 2 -69 16 56 31 Dec 18 2 -74 17 60 30 Sep 18 2 -74 17 61 30 Jun 18 2 -72 17 59 31 Mar 18 2 -67 17 54 31 Dec 17 2 -61 16 48 30 Sep 17 1 -53 15 40 30 Jun 17 1 -52 14 40 31 Mar 17 1 -47 13 36 31 Dec 16 1 -47 13 32 30 Sep 16 1 -45 11 26 30 Jun 16 1 -87 11 16 31 Mar 16 1 -105 12 13 31 Dec 15 1 -104 12 10 30 Sep 15 0 -100 11 8 30 Jun 15 0 -53 14 8 31 Mar 15 0 -33 12 10 31 Dec 14 0 -26 11 10 30 Sep 14 0 -31 11 10 30 Jun 14 0 -72 7 8 31 Mar 14 0 -67 6 5
Ingresos de calidad: SNDX actualmente no es rentable.
Margen de beneficios creciente: SNDX actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: SNDX no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 37.2% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de SNDX en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: SNDX no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (16.6%).
Rentabilidad financiera
Alta ROE: SNDX tiene una rentabilidad financiera negativa (-81.07%), ya que actualmente no es rentable.
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
